XOMA Royalty (XOMA) Cash & Current Investments (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Cash & Current Investments came in at $86.1 million in Q1 2026, up 1088.9% year-on-year from $7.2 million in Q1 2025, and down 2.55% quarter-over-quarter from $88.3 million in Q4 2025.
XOMA Royalty (XOMA) Cash & Current Investments (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Cash & Current Investments across 17 years of filings, most recently posting $86.1 million for Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $86.1 million, up 1088.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.1 million (up 1088.9% YoY), and the FY2025 annual result was $88.3 million, up 756.68% from the prior year.
- Cash & Current Investments came in at $86.1 million for Q1 2026 at XOMA Royalty, down from $88.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $153.4 million in Q4 2023 to a low of $4.8 million in Q3 2024.
- The 5-year median for Cash & Current Investments is $44.6 million (2023), against an average of $61.5 million.
- Across the five-year window, Cash & Current Investments plunged 94.69% in 2025 and surged 1088.9% in 2026, its largest moves.
- XOMA Royalty's Cash & Current Investments stood at $30.6 million in 2022, then jumped by 400.9% to $153.4 million in 2023, then sank by 93.28% to $10.3 million in 2024, then jumped by 756.68% to $88.3 million in 2025, then retreated by 2.55% to $86.1 million in 2026.
- The last three Cash & Current Investments figures came in at $86.1 million (Q1 2026), $88.3 million (Q4 2025), and $55.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - | 86.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.10 Mn |
| Dec 31, 2025 | 88.35 Mn |
| Sep 30, 2025 | 55.47 Mn |
| Jun 30, 2025 | 15.79 Mn |
| Mar 31, 2025 | 7.24 Mn |
| Dec 31, 2024 | 10.31 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 144.60 Mn |
| Mar 31, 2024 | 136.43 Mn |
| Dec 31, 2023 | 153.45 Mn |
| Sep 30, 2023 | 33.69 Mn |
| Jun 30, 2023 | 31.72 Mn |
| Mar 31, 2023 | 44.61 Mn |
| Dec 31, 2022 | 30.64 Mn |
| Sep 30, 2022 | 30.64 Mn |
| Jun 30, 2022 | 83.71 Mn |
| Mar 31, 2022 | 88.60 Mn |
| Dec 31, 2021 | 94.10 Mn |
| Sep 30, 2021 | 72.17 Mn |
| Jun 30, 2021 | 81.26 Mn |